teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 55 Projects Releases Packages Wiki Activity Actions 1.3k

auto-fix: strip 2 broken wiki links

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-03-21 04:35:35 +00:00
parent 9c0ac2552e
commit 7007848c9d
1 changed files with 2 additions and 2 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

4
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -127,14 +127,14 @@ Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded an
### Additional Evidence (challenge)
*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20*
*Source: 2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics | Added: 2026-03-20*
India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033.
---
### Additional Evidence (challenge)
*Source: [[2026-03-21-natco-semaglutide-india-day1-launch-1290]] | Added: 2026-03-21*
*Source: 2026-03-21-natco-semaglutide-india-day1-launch-1290 | Added: 2026-03-21*
Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on March 20, 2026, the day the patent expired. This is 90% below innovator pricing and 2-3x lower than analyst projections made days earlier ($40-77/month within a year). 50+ manufacturers from 40+ companies are entering the market, with Sun Pharma, Zydus, Dr. Reddy's, and Eris launching on Day 1. The 'inflationary through 2035' timeline is empirically wrong for international markets—price compression is happening in 2026, not 2030+.